In the past week, CVAC stock has gone up by 2.01%, with a monthly gain of 11.32% and a quarterly surge of 1.67%. The volatility ratio for the week is 6.78%, and the volatility levels for the last 30 days are 6.24% for CureVac N.V The simple moving average for the past 20 days is 0.69% for CVAC’s stock, with a -2.99% simple moving average for the past 200 days.
Is It Worth Investing in CureVac N.V (NASDAQ: CVAC) Right Now?
CureVac N.V (NASDAQ: CVAC) has a higher price-to-earnings ratio of 5.61x compared to its average ratio. CVAC has 36-month beta value of 2.58. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CVAC is 93.63M, and currently, short sellers hold a 4.21% ratio of that float. The average trading volume of CVAC on December 27, 2024 was 502.57K shares.
CVAC) stock’s latest price update
CureVac N.V (NASDAQ: CVAC)’s stock price has decreased by 0.00 compared to its previous closing price of 3.05. However, the company has seen a 2.01% increase in its stock price over the last five trading sessions. marketbeat.com reported 2024-12-16 that Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Leerink Partners repeating the rating for CVAC by listing it as a “Market Perform.” The predicted price for CVAC in the upcoming period, according to Leerink Partners is $4 based on the research report published on April 25, 2024 of the current year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $13. The rating they have provided for CVAC stocks is “Outperform” according to the report published on June 08th, 2023.
UBS gave a rating of “Buy” to CVAC, setting the target price at $18 in the report published on January 19th of the previous year.
CVAC Trading at 6.73% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.23% of loss for the given period.
Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 6.78%, as shares surge +6.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.92% upper at present.
During the last 5 trading sessions, CVAC rose by +2.51%, which changed the moving average for the period of 200-days by -9.05% in comparison to the 20-day moving average, which settled at $3.03. In addition, CureVac N.V saw -27.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVAC starting from Pierre Kemula, who proposed sale 55 shares at the price of $3.08 back on Sep 27 ’24. After this action, Pierre Kemula now owns shares of CureVac N.V, valued at $169 using the latest closing price.
Pierre Kemula, the affiliate of CureVac N.V, proposed sale 34,000 shares at $3.10 during a trade that took place back on Sep 25 ’24, which means that Pierre Kemula is holding shares at $105,400 based on the most recent closing price.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.7 for the gross margin
The net margin for CureVac N.V stands at 0.2. The total capital return value is set at 0.17. Equity return is now at value 17.08, with 13.38 for asset returns.
Currently, EBITDA for the company is -234.09 million with net debt to EBITDA at -3.28. When we switch over and look at the enterprise to sales, we see a ratio of 0.28. The receivables turnover for the company is 26.09for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.20.
Conclusion
To put it simply, CureVac N.V (CVAC) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
